Opko健康 OPK 深 滬
等待開盤 03-26 09:30:00 美东时间
1.19
+0.060
+5.31%
華盛通- 最 高1.20
- 今 開1.14
- 成交量 342.66万股
- 最 低 1.1399
- 昨 收 1.13
- 總市值 9.03亿
- 52周最高 1.60
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 1.10
- 委 比 -3.52%
- 總股本 7.59亿
- 歷史最高 19.20
- 量 比 0.95
- 振 幅 5.32%
- 歷史最低 0.8516
- 每 手 1
- 風險率 0.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Opko Health Adds Independent Director to Strengthen Governance
Opko Health ( ($OPK) ) has provided an update. On March 18, 2026, OPKO Health a...
03-20 05:19
Vesicor Therapeutics names Michael Tolentino CEO as Luo Feng becomes CSO
Vesicor Therapeutics names Michael Tolentino CEO as Luo Feng becomes CSO Vesicor Therapeutics, a proposed de-SPAC target of Black Hawk, appointed Michael Tolentino as CEO effective March 17, 2026, replacing founder Luo Feng. Luo Feng moved to Chief Scientific Officer at Vesicor. Michael Tolentino pr
03-19 10:43
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Vesicor Therapeutics appoints Michael Tolentino, M.D., as CEO, succeeding Luo Feng, Ph.D., who becomes Chief Scientific Officer. Tolentino brings over 20 years of biotech experience, including key roles in drug development and leadership at prominent firms. Vesicor is preparing for a de-SPAC merger with Black Hawk Acquisition Corporation and aims to advance its IND application for cancer therapeutics. Tolentino emphasizes leveraging Vesicor's tec...
03-19 02:42
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5
Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform and lowers the price target from $2.25 to $1.5.
03-02 23:44
电话会总结 ｜ OPKO Health(OPK)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 基于OPKO Health业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **整体财务表现：** - 2025年第四季度合并营收为1.485亿美元，同比下降19.1%（2024年第四季度为1.836亿美元） - 合并营业亏损3,830万美元，较2024年第四季度的3,310万美元亏损扩大 - 净亏损3,130万美元（每股亏损0.04美元），而2024年第四季度净收入为1,400万美元（每股收益0.01美元） **分部门业绩：** - 诊断业务营收7,110万美元，同比下降31.0%（2024年第四季度为1.031亿美元） - 制药业务营收
02-27 12:08
Earnings Breakdown: OPKO Health Q4
OPKO Health (NASDAQ:OPK) just disclosed its Q4 earnings on Thursday, February 2...
02-27 05:19
OPKO Health Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $148.500M Beat $139.757M Estimate
OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 41.18 percent. This is a 300 percent decrease over earnings of $0.02 per share from the same
02-27 05:13
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilitiesThe companies have accelerated this program and aim to file an
02-04 21:05
